S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Greenwich LifeSciences Stock Forecast, Price & News

-1.59 (-4.58%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
10,731 shs
Average Volume
252,897 shs
Market Capitalization
$430.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GLSI News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Greenwich LifeSciences logo

About Greenwich LifeSciences

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.19 per share


Net Income
$-1.86 million
Pretax Margin




Free Float
Market Cap
$430.90 million
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

1.91 out of 5 stars

Medical Sector

707th out of 1,391 stocks

Pharmaceutical Preparations Industry

334th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Greenwich LifeSciences (NASDAQ:GLSI) Frequently Asked Questions

Is Greenwich LifeSciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Greenwich LifeSciences stock.
View analyst ratings for Greenwich LifeSciences
or view top-rated stocks.

Are investors shorting Greenwich LifeSciences?

Greenwich LifeSciences saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 85,300 shares, a decrease of 21.2% from the October 31st total of 108,300 shares. Based on an average daily trading volume, of 36,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.1% of the company's shares are sold short.
View Greenwich LifeSciences' Short Interest

What price target have analysts set for GLSI?

2 equities research analysts have issued 1 year price objectives for Greenwich LifeSciences' shares. Their forecasts range from $75.00 to $78.00. On average, they expect Greenwich LifeSciences' stock price to reach $76.50 in the next year. This suggests a possible upside of 131.1% from the stock's current price.
View analysts' price targets for Greenwich LifeSciences
or view top-rated stocks among Wall Street analysts.

Who are Greenwich LifeSciences' key executives?

Greenwich LifeSciences' management team includes the following people:

When did Greenwich LifeSciences IPO?

(GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO.

What is Greenwich LifeSciences' stock symbol?

Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI."

Who are Greenwich LifeSciences' major shareholders?

Greenwich LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Invesco Ltd. (1.14%), Geode Capital Management LLC (0.44%), Millennium Management LLC (0.12%), Tibra Equities Europe Ltd (0.10%), Bank of New York Mellon Corp (0.08%) and OLD Mission Capital LLC (0.06%). Company insiders that own Greenwich LifeSciences stock include Frank Joseph Daugherty and Snehal Patel.
View institutional ownership trends for Greenwich LifeSciences

Which institutional investors are selling Greenwich LifeSciences stock?

GLSI stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, and California State Teachers Retirement System.
View insider buying and selling activity for Greenwich LifeSciences
or view top insider-selling stocks.

Which institutional investors are buying Greenwich LifeSciences stock?

GLSI stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tibra Equities Europe Ltd, OLD Mission Capital LLC, Geode Capital Management LLC, UBS Group AG, Bank of New York Mellon Corp, Jane Street Group LLC, and Royal Bank of Canada. Company insiders that have bought Greenwich LifeSciences stock in the last two years include Frank Joseph Daugherty, and Snehal Patel.
View insider buying and selling activity for Greenwich LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Greenwich LifeSciences' stock price today?

One share of GLSI stock can currently be purchased for approximately $33.10.

How much money does Greenwich LifeSciences make?

Greenwich LifeSciences has a market capitalization of $430.90 million.

How many employees does Greenwich LifeSciences have?

Greenwich LifeSciences employs 2 workers across the globe.

What is Greenwich LifeSciences' official website?

The official website for Greenwich LifeSciences is www.greenwichlifesciences.com.

How can I contact Greenwich LifeSciences?

The company can be reached via phone at 832-819-3232 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.